Israeli researchers at Technion find two proteins that can suppress Cancer

▴ Israeli researchers at Technion find two proteins that can suppress Cancer
Now antibodies for cancer treatment are being researched

A team of Israeli researchers at the Technion has discovered two proteins that can suppress cancer and control the cells’ growth and development.

The study was conducted in the laboratory of Prof. Aaron Ciechanover, an Israeli Nobel-prize winner in chemistry, and led by Dr. Yelena Kravtsova-Ivantsiv. The team included research students and physicians from the Rambam, Carmel and Hadassah Medical Centers.

In a paper published in the journal Cell last week, the researchers showed how the proteins could repress cancerous tissues and detailed how a high concentration of a protein called KPC1 and another called p50 in the tissue can protect it from cancerous tumors.

The research also detailed how the ubiquitin process — a cell system responsible for breaking down damaged proteins that can harm cells and tissues and co-discovered by Ciechanover, for which he won the Nobel — has a role in the mechanism.

The study was done on human tumors grown in mice, and samples of human tumors.

Ciechanover told PR Newswire that many more years of research are needed “to establish the research and gain a solid understanding of the mechanisms behind the suppression of the tumors. The development of a drug based on this discovery is a possibility, although not a certainty, and the road to such a drug is long and far from simple.”

Ciechanover, now president of the Israel Cancer Society, won the 2004 Nobel Prize in chemistry, for the discovery of ubiquitin-mediated protein degradation. In response to the latest development, Ceichanover warned that it will take many more years before scientists can hope to gain a solid understanding of the mechanisms behind the suppression of cancerous tumors.

“The development of a drug based on this discovery is a possibility, although not a certainty, and the road to such a drug is long and far from simple,” he cautioned.

But the current research, which was published in the April 9, 2015 edition of CELL, is also intriguing because it provides further evidence of the relationship between inflammation and cancer, first suggested in 1863 by German pathologist Rudolph Virchow and confirmed over the years.

Ever since the discovery of NF-κB nearly 30 years ago, many scientists have written about its multifaceted involvement in inflammation and cell proliferation, survival and transformation. NF-κB is activated by the ubiquitin system’s KPC1 regulator.

“Overall, KPC1 regulation of NF-κB1 processing appears to constitute an important balancing step among the stimulatory and inhibitory activities of the transcription factor in cell growth control,” the study’s authors conclude.

The Technion team will continue its line of research to find more clues toward solving this puzzle.

Tags : #CancerAntibodies #CancerTreatmentBreakthrough #IsraeliScientists #DrYelenaKravtsova #Technion #CancerTreatment #LatestPharmaNewsAug26

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Surviving Against the Odds: Steven Spinale's Journey After an Ingrown Hair Turns DeadlyMarch 29, 2024
10 reasons why media research and Planning are essential in Healthcare marketingMarch 29, 2024
The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024